ArticleOncoTargets and therapy2021
Identification and Validation a Necroptosis‑related Prognostic Signature and Associated Regulatory Axis in Stomach Adenocarcinoma.
Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 97 citations in OpenAlex.
- Identification of Inflammatory Cell Death-Related Prognostic Signature and Its Regulatory Mechanism in Lung Adenocarcinoma.Cancer medicine · 2026Article
- Establishment of a Prognostic Necroptosis-Related lncRNA Signature in Ovarian Cancer.Combinatorial chemistry & high throughput screening · 2026Article
- Development and validation of transient receptor potential channel-related signature for predicting prognosis in patients with lung adenocarcinoma.Oncology letters · 2025Article
- Inhibition of gastric adenocarcinoma proliferation by WSGC@MS: Role of KEAP1/NRF2 signaling pathway and autophagy regulation.Materials today. Bio · 2025Article
- Systematic benchmarking of large Language models in programmed cell death-oriented gastric cancer research: a comparative analysis of DeepSeek‑V3, DeepSeek‑R1, and Claude 3.5.Discover oncology · 2025Article
- The Role ofIranian journal of public health · 2025Article
- Cell death in tumor microenvironment: an insight for exploiting novel therapeutic approaches.Cell death discovery · 2025Review
- Toll-like receptor 3: a double-edged sword.Biomarker research · 2025Review
- Machine learning based immune evasion signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.Frontiers in cell and developmental biology · 2025Article
- Prognostic Implications and Immune Landscape Analysis of Necroptosis-associated Gene Signatures in Acute Myeloid Leukemia.Journal of Cancer · 2025Article
- Article
- Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.BMC cancer · 2024Article
- TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis.EMBO molecular medicine · 2024Article
- Article
- Identification and Validation of a Necroptosis-Related Prognostic Model in Tumor Recurrence and Tumor Immune Microenvironment in Breast Cancer Management.Journal of inflammation research · 2024Article
- Identification of TNFRSF1A as a potential biomarker for osteosarcoma.Cancer biomarkers : section A of Disease markers · 2024Article
- Construction of stomach adenocarcinoma prognostic signature based on anoikis-related lncRNAs and clinical significance.The Libyan journal of medicine · 2023Article
- Identification of necroptosis-related lncRNAs for prognosis prediction and screening of potential drugs in patients with colorectal cancer.World journal of gastrointestinal oncology · 2023Article
- Article
- Identification and Validation a Necroptosis-Related Prognostic Signature in Cervical Cancer.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) ranks fifth in global cancer incidence and third in cancer-related mortality. The prognosis of GC patients was poor. Necroptosis is a type of regulated cell death mediated by RIP1, RIP3, and MLKL. Necroptosis was found to be involved in antitumor immunity in the cancer immunotherapy.
methodsLASSO Cox regression analysis was performed to construct a prognostic signature. Bioinformatics analysis was performed to construct a lncRNA-miRNA-mRNA regulatory axis. qRT-PCR was performed to verify the expression and prognosis of hub gene in STAD.
resultsMost of necroptosis regulators were upregulated, while the mRNA level of TLR3, ALDH2, and NDRG2 was downregulated in STAD versus gastric tissues. The genetic mutation and copy number variation of necroptosis regulator in STAD were also summarized. GO and KEGG pathways analysis revealed that these necroptosis regulators were mainly involved in programmed necrotic cell death and TNF signaling pathway. A necroptosis‑related prognostic signature based on four genes (EZH2, PGAM5, TLR4, and TRAF2) had a good performance in predicting the prognosis of STAD patients. We also identified lncRNA SNHG1/miR-21-5p/TLR4 regulatory axis in the progression in STAD. Verification study suggested that the hub gene TLR4 upregulated in STAD and correlated with a poor overall survival. Moreover, Cox regression analysis revealed that TLR4 expression and clinical stage were independent factors affecting the prognosis of STAD patients.
conclusionWe performed a comprehensive bioinformatics analysis and identified a necroptosis‑related prognostic signature and a lncRNA SNHG1/miR-21-5p/TLR4 regulatory axis in STAD. Further study should be performed to confirm our result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.